Abstract
Patients with depression require thorough clinical assessment, which should include symptom profile, severity and staging, personality factors, antecedent and concurrent psychiatric comorbidity, physical comorbidity, neurocognitive function, exposure to stressors in early life (e.g. trauma) or recently (e.g. bereavement), and protective factors. The presence of anxiety symptoms in a depressed patient is associated with more severe depression, increased suicidality and worse outcomes compared with non-anxious depression. A network meta-analysis of antidepressant treatments found that agomelatine, citalopram, amitriptyline, escitalopram, mirtazapine, paroxetine, venlafaxine and vortioxetine were all significantly more effective than other antidepressants for the treatment of depression, and that agomelatine, citalopram, escitalopram, fluoxetine, sertraline and vortioxetine were better tolerated than other antidepressants. Agomelatine has been shown to have two major effects—relieving depressive symptoms, and supporting symptomatic and functional recovery—and these benefits have been demonstrated in patients with depression as well as in patients with generalised anxiety disorder, including those with more severe symptoms. Agomelatine has also been shown to be efficacious and well tolerated in patients with depression plus concomitant anxiety symptoms. A pooled analysis of data from six agomelatine studies of depression (three placebo-controlled and three with active comparators—fluoxetine, sertraline and venlafaxine) found that agomelatine was significantly more effective than placebo at relieving the anxiety subscore on the Hamilton Depression Rating Scale, and that the difference between agomelatine and placebo was even more marked in the subgroup of patients with severe anxiety symptoms at baseline. Irrespective of the pharmacotherapy used in patients with depression, the likelihoods of response and remission are increased when pharmacotherapy is combined with psychotherapy, with this approach being more effective than either pharmacotherapy or psychotherapy alone. Persistence with treatment is important, and clinicians should therefore encourage patients to keep trying to obtain relief.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
A thorough clinical assessment of depression, including symptom profile, is required to effectively tailor treatment. |
Clinicians should have a high index of suspicion for anxiety symptoms in patients with depression, and should treat anxious depression with vigilance and vigour. |
Severe anxiety in a depressed patient is associated with increased suicidality and worse outcomes compared with non-anxious depression. |
Agomelatine is an effective antidepressant with benefits on both symptoms and psychosocial function in patients with generalised anxiety disorder, as well as in patients with depression, including depression with severe anxiety symptoms. |
Irrespective of the antidepressant used, the combination of psychotherapy and pharmacotherapy is more effective for depression than either treatment modality on its own. |
Introduction
Depression is not a single homogenous entity; rather it is a condition that may have a number of different symptom domains, including anxiety, and its treatment should be tailored accordingly. Indeed, the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) [1] and the 11th revision of the International Classification of Diseases (ICD-11) [2] include specifiers to improve the precision of the diagnosis of depression. In addition, the Research Domain Criteria framework provides an alternative approach that moves the focus away from diagnostic entities, while focussing on the underlying pathophysiological processes that account for transdiagnostic and coexisting symptoms [3].
The fact that there are multiple ways in which an individual patient can meet the diagnostic criteria for major depressive disorder (MDD) may contribute to current guidelines having only partial treatment success. The aims of the current commentary are to outline how a more detailed clinical characterisation of MDD may be useful in individualising treatment decisions, and to review the evidence base for pharmacotherapy and psychotherapy in patients with MDD and symptoms of anxiety. The discussion of pharmacotherapy focuses on agomelatine, and its efficacy in this specific patient population.
This commentary is based on content from a virtual symposium sponsored by Servier at the 33rd International College of Neuropsychopharmacology (CINP) World Congress in June 2022, Taipei, Taiwan. The commentary is based on previously conducted studies and does not contain any new studies with human participants or animals performed by the author.
Assessment of the Patient with Depression
In order to personalise the treatment of depression, it is essential to conduct a thorough clinical assessment and history taking [4]. This should cover a range of domains, including the patient’s symptom profile, clinical subtypes, severity and staging, personality factors, antecedent and concurrent psychiatric comorbidity, physical comorbidity, neurocognitive function, traumatic stressors in early life (e.g. trauma) or recently (e.g. bereavement), and protective factors [4]. Protective factors contribute to resilience, and can be remembered using the acronym SOCIAL, for Social resources, Occupation, Children and family, Income and material resources, Abilities/appearance/health, etc., and Love/sex in an intimate relationship [5]. However, such clinical assessments need to be culturally congruent.
During clinical assessment, anxiety is identified by the presence of at least two of the following symptoms: feelings of being keyed up or tense, having difficulty concentrating, restlessness, and fear that something awful may happen or that the patient may lose control [1]. There is evidence that the neurobiological profile of depression with anxiety differs from that of non-anxious depression, with greater dysregulation of immune and hypothalamic–pituitary–adrenal axis function, more marked cortical thinning, and changes in the functional pattern of corticolimbic pathways [6]. The presence of anxiety in a depressed patient calls for treatment to be undertaken with increased vigilance and vigour because anxious depression is associated with greater severity of depression [7], increased suicidality [7] and worse outcomes [6] compared with depression without concomitant anxiety.
Pharmacotherapy Considerations
There are surprisingly few data comparing the efficacy of antidepressant therapies in patients with anxious depression. However, a large network meta-analysis of antidepressant treatments found that all were significantly more effective than placebo for the treatment of depression (not specifically anxious depression), and that agomelatine, citalopram, amitriptyline, escitalopram, mirtazapine, paroxetine, venlafaxine and vortioxetine were more effective than other antidepressants [8]. This network meta-analysis also found that agomelatine, citalopram, escitalopram, fluoxetine, sertraline and vortioxetine were better tolerated than other antidepressants, based on the number of patients discontinuing treatment because of adverse events [8].
Focus on Agomelatine
Agomelatine, a first-in-class antidepressant with a non-monoaminergic mechanism of action was approved in Europe in 2009 for the treatment of MDD [9]. Agomelatine is both a melatonergic agonist and an antagonist of serotonin 2C (5-HT2C) receptors [9]. It is thought that these two mechanisms work synergistically to improve depressive symptoms, restore circadian rhythms, and favourably influence anxiety, sleep and sexual function [9]. Recent work has suggested a number of neurobiological mechanisms which may be involved in the response of anxiety symptoms to agomelatine [10].
Clinically, agomelatine has been shown to have two major effects: (1) relieving depressive symptoms [8], and (2) supporting symptomatic and functional recovery [11, 12]. In a network meta-analysis comparing different antidepressant agents, agomelatine was significantly more effective for depression than the reference comparator (reboxetine), which was not demonstrated for some of the other antidepressants in the analysis (Fig. 1) [8]. Moreover, in placebo-controlled studies, agomelatine proved to be effective in achieving both symptomatic and functional remission (Fig. 2a) and in maintaining remission over time (Fig. 2b) [11, 12].
A 2021 network meta-analysis of 42 randomised clinical trials of depression examined the effect of different antidepressants on functional outcomes, as measured by the Sheehan Disability Scale (SDS), in patients with MDD [13]. Using the surface area under the cumulative ranking curve to compare agents, agomelatine ranked best in terms of functional improvement in the domains of work/school, social/leisure activities, and family/home responsibilities [13].
The benefits of agomelatine on symptomatic and functional recovery have also been demonstrated in patients with generalised anxiety disorder (GAD). A meta-analysis of three studies in which patients with GAD were randomised to placebo or agomelatine found that agomelatine significantly ameliorated anxiety symptoms compared with placebo, with a mean 6.30-point difference in the Hamilton Anxiety Rating Scale (HAM-A) [14] in the overall cohort and a 6.49-point difference in the subgroup with the most severe GAD at baseline (HAM-A score ≥ 25). This was associated with a significantly higher rate of symptomatic response (≥ 50% reduction in HAM-A score) and remission (total HAM-A total score ≤ 7 at the last post-baseline evaluation) in the agomelatine- than the placebo-treated patients. In the subgroup with severe GAD, a symptomatic response was seen in 67.6% of patients receiving agomelatine versus 31.6% of those receiving placebo (p < 0.001), and symptomatic remission was seen in 38.2% versus 17.5%, respectively (p < 0.0001) [14]. Rates of functional response (SDS total score ≤ 12) and remission (SDS total score ≤ 6) were also significantly higher in patients receiving agomelatine than in those receiving placebo, including in the severe GAD subgroup, which showed functional response rates of 77.6% versus 41.2%, respectively (p = 0.003), and functional remission rates of 54.4% versus 23.7% (p < 0.0001), respectively [14].
GAD is characterised by both psychic and somatic symptoms. In a pooled analysis of three randomised placebo-controlled trials of agomelatine in patients with GAD, the subgroup of patients with prominent somatic anxiety (HAM-A somatic subscore ≥ 14) derived a significant benefit from agomelatine compared with placebo across all domains of anxiety (HAM-A total score, somatic subscore, and psychic subscore), as well as in functional domains (SDS total score; Fig. 3) [15].
Agomelatine has also been shown to be efficacious and well tolerated in patients with MDD, including those with concomitant anxiety symptoms [16]. A pooled analysis of data from six agomelatine studies (three placebo-controlled and three with active comparators—fluoxetine, sertraline and venlafaxine) found that agomelatine was significantly more effective than placebo at relieving the anxiety subscore on the Hamilton Depression Rating Scale (HAM-D; items 10 and 11) [16]. The difference between agomelatine and placebo was even more marked in the subgroup of patients with more severe anxiety symptoms at baseline (i.e. those with a HAM-D score on items 10 and 11 of ≥ 5) [16].
Psychotherapy Considerations
There are surprisingly few comparative data on the efficacy of pharmacotherapy versus psychotherapy for anxious depression. However, a meta-analysis by Cuijpers and colleagues found that pharmacotherapy and psychotherapy were similarly effective in achieving a response in patients with depression (i.e. a 50% reduction in depressive symptomatology) [17]. The relative risk (RR) for response with psychotherapy versus pharmacotherapy was 0.99 [95% confidence interval (CI) 0.92–1.08], but the combination of psychotherapy and pharmacotherapy was significantly more effective than either form of therapy alone [RR of 1.27 (95% CI 1.14–1.39) versus psychotherapy alone and RR of 1.25 (95% CI 1.14–1.7) versus pharmacotherapy alone]. Similar results were seen in terms of remission, with the RR for psychotherapy versus pharmacotherapy being 1.01 (95% CI 0.93–1.01), while the RR for the combination versus psychotherapy was 1.22 (95% CI 1.08–1.9), and versus pharmacotherapy was 1.23 (95% CI 1.09–1.39). In addition, acceptability (based on study dropout for any reason) was significantly better with combined treatment [RR 1.23 (95% CI 1.05–1.45)] and psychotherapy alone [RR 1.17 (95% CI 1.02–1.32)] versus pharmacotherapy alone, which may be related to the tolerability of antidepressant agents. The combination of pharmacotherapy and psychotherapy may maximise the benefits of pharmacotherapy in achieving symptomatic relief and of psychotherapy in consolidating early gains into long-term remission.
The World Mental Health Surveys, conducted among 80 332 individuals from 16 countries, found that patients with a lifetime history of depression often have to repeatedly seek treatment until they find a therapy that is helpful [18]. Overall, 68.2% of these patients obtained treatment that they perceived as helpful, but the remaining 31.8% stopped seeking treatment when therapies did not provide the relief they were looking for. Among those projected to persist through 10 health professionals, 93.9% would receive a treatment that helped them, but only 21.5% of patients would persist through this number of treatment attempts. The number of comorbid anxiety disorders did not affect these results [18]. Analogous data on GAD also emphasise the importance of persisting with treatment [19].
Conclusions
Major depression requires individualised assessment including assessment of anxiety, and a personalised approach to therapy that aims at both symptomatic and functional improvement. Patients with concomitant anxiety symptoms are more likely to suffer from severe depression, attempt suicide, and have worse outcomes than patients without anxiety symptoms. Such individuals deserve robust intervention, and data from network meta-analyses of interventions for depression may be useful in guiding the choice of antidepressant. In addition, concomitant psychotherapy may increase the likelihood of response and remission. Furthermore, the importance of persistence with treatment should be emphasised to patients.
References
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edition. Arlington, VA, USA: American Psychiatric Association; 2013.
World Health Organization. International Classification of Diseases, Eleventh Revision (ICD-11). 2019. https://icd.who.int/browse11.
Cuthbert BN. Research Domain Criteria: toward future psychiatric nosologies. Dialogues Clin Neurosci. 2015;17(1):89–97.
Maj M, Stein DJ, Parker G, et al. The clinical characterization of the adult patient with depression aimed at personalization of management. World Psychiatry. 2020;19(3):269–93.
Nesse RM. Good reasons for bad feelings: insights from the frontier of evolutionary psychiatry: Penguin; 2019.
Gaspersz R, Nawijn L, Lamers F, Penninx B. Patients with anxious depression: overview of prevalence, pathophysiology and impact on course and treatment outcome. Curr Opin Psychiatry. 2018;31(1):17–25.
Hasin DS, Sarvet AL, Meyers JL, et al. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry. 2018;75(4):336–46.
Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357–66.
de Bodinat C, Guardiola-Lemaitre B, Mocaer E, Renard P, Munoz C, Millan MJ. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov. 2010;9(8):628–42.
Millan MJ. Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action. Ther Adv Psychopharmacol. 2022;12:20451253221105128.
Kennedy SH, Avedisova A, Belaidi C, Picarel-Blanchot F, de Bodinat C. Sustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months. Eur Neuropsychopharmacol. 2016;26(2):378–89.
Kennedy SH, Heun R, Avedisova A, et al. Effect of agomelatine 25–50mg on functional outcomes in patients with major depressive disorder. J Affect Disord. 2018;238:122–8.
Cao B, Xu L, Chen Y, et al. Comparative efficacy of pharmacological treatments on measures of self-rated functional outcomes using the Sheehan Disability Scale in patients with major depressive disorder: a systematic review and network meta-analysis. CNS Spectr. 2021:1—9.
Stein DJ, Khoo JP, Picarel-Blanchot F, Olivier V, Van Ameringen M. Efficacy of agomelatine 25–50 mg for the treatment of anxious symptoms and functional impairment in generalized anxiety disorder: a meta-analysis of three placebo-controlled studies. Adv Ther. 2021;38(3):1567–83.
P.0035 Meta-analysis of short-term trials with agomelatine in the treatment of Generalised Anxiety Disorder in patients with prominent somatic symptoms [Congress abstract]. Eur Neuropsychopharmacol. 2022. In press.
Stein DJ, Picarel-Blanchot F, Kennedy SH. Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression. Hum Psychopharmacol. 2013;28(2):151–9.
Cuijpers P, Noma H, Karyotaki E, Vinkers CH, Cipriani A, Furukawa TA. A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry. 2020;19(1):92–107.
Harris MG, Kazdin AE, Chiu WT, et al. Findings from World Mental Health Surveys of the perceived helpfulness of treatment for patients with major depressive disorder. JAMA Psychiatry. 2020;77(8):830–41.
Stein DJ, Kazdin AE, Ruscio AM, et al. Perceived helpfulness of treatment for generalized anxiety disorder: a World Mental Health Surveys report. BMC Psychiatry. 2021;21(1):392.
Acknowledgements
Funding
Servier provided funding for the CINP symposium and for the preparation of the supplement. This funding includes payment of the journal’s Rapid Service Fee.
Medical writing and/or editorial assistance
We would like to thank Catherine Rees who provided editorial support for the first draft on behalf of Springer Healthcare Communications. This medical writing assistance was funded by Servier.
Authorship
Dr Stein meets the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, takes responsibility for the integrity of the work as a whole, and has given his approval for this version to be published.
Author contributions
Dr Stein conceptualised the content of the presentation and article, developed the content for presentation, critically reviewed and revised all drafts of the article, and approved the article for submission.
Prior presentation
This article and the accompanying articles in this supplement are based on presentations made by the authors at a Servier-funded virtual symposium titled “Anxiety Symptoms in Depression: Contemporary Treatment Approaches”, held in association with the 33rd International College of Neuropsychopharmacology (CINP) World Congress in June 2022, in Taipei, Taiwan.
Disclosures
Dr Stein has received research grants and/or consultancy honoraria from Discovery Vitality, Johnson & Johnson, Kanna, Lundbeck, Orion, Servier, Takeda, and Vistagen.
Compliance with ethics guidelines
This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by the author.
Data availability
Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Stein, D.J. Evidence-Based Pharmacotherapy of Anxiety Symptoms in Patients with Major Depressive Disorder: Focus on Agomelatine. Neurol Ther 12 (Suppl 1), 13–19 (2023). https://doi.org/10.1007/s40120-023-00470-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40120-023-00470-z